Powered by Clearbit

Nanjing Pharmaceutical Co., Ltd. (SHA: 600713)

Financial Highlights as of 12/31/2020 in CNY

Income Statement(In Thousands)
Total Revenue39,817,364
EBITDA37,997,991
Operating Income38,311,528
Net Income376,413
EPS - Net Income - Diluted0.36
Earnings per Share - Basic0.36
Balance Sheet(In Thousands)
Total Assets23,409,572
Current Assets21,164,734
Total Liabilities19,152,029
Long Term Debt1,026,981
Stockholders' Equity4,257,543
Current Liabilities17,202,514
Cash Flow Statement(In Thousands)
Cash from Operations(1,152,463)
Cash from Investing(216,007)
Cash from Financing749,337
Cash & Cash Equivalents, Beginning of Year2,010,038
Cash & Cash Equivalents, End of Year1,390,905
Management Effectiveness
ROA % (Net)1.65
ROE % (Net)9.08
ROI % (Operating)434.68
Profitability Ratios
Operating Margin96.22
EBITDA Margin %95.43
Calculated Tax Rate %0.55
Profit Margin (TTM)0.95
Asset Management
Total Asset Turnover1.75
Receivables Turnover3.42
Inventory Turnover10.20
Property Plant & Equip Turnover35.85
Cash & Equivalents Turnover22.17
Debt Management
Interest Coverage5,005.22
Long Term Debt/Equity0.24
Long Term Debt as % of Invested Capital9.87
Total Debt/Equity1.44
Accounts Payable Turnover8.30
Accrued Expenses Turnover229.52
Liquidity Indicators
Quick Ratio0.81
Current Ratio1.23
Net Current Assets as % of Total Assets16.93
Revenue to Assets1.70